Walking and Resistance Bands During Chemo Reduced Cognitive Decline in a 687-Patient Trial

National Comprehensive Cancer Network

The term "chemo brain" is not in any medical textbook, but oncologists hear it constantly. Patients describe it as fog - difficulty concentrating, trouble finding words, a sense that their thinking has slowed. It is one of the most common complaints during chemotherapy, and until recently, there was little evidence that anything could be done about it.

A new study offers a concrete answer: structured exercise during chemotherapy appears to reduce cognitive decline, at least for patients receiving treatment on a two-week cycle. The research, published in the March 2026 issue of JNCCN - Journal of the National Comprehensive Cancer Network, is the first nationwide, multicenter, phase III randomized controlled trial to test an exercise prescription specifically for chemotherapy-related cognitive impairment.

687 patients, 20 centers, a simple prescription

The trial enrolled 687 patients from 20 community oncology practices across the United States, all part of the University of Rochester Cancer Center NCI Community Oncology Research Program. Patients were receiving chemotherapy for the first time, did not have distant metastases, and were enrolled between 2009 and 2014. The majority were women, most had undergone surgery, and breast cancer was the most common diagnosis.

Patients were randomized to receive either usual chemotherapy care or usual care plus EXCAP (Exercise for Cancer Patients) - an individually tailored exercise prescription consisting of walking and simple resistance band exercises. The program was taught through a teach-back method to ensure correct technique. Participants received pedometers and kept daily diaries of their walking steps and resistance band activity.

The intervention was deliberately modest. No gym memberships. No supervised sessions. Just walking and resistance bands, done at home, adjusted to individual capacity.

Two-week cycles hit a sweet spot

The key finding was specific to chemotherapy timing. Patients receiving two-week chemotherapy cycles who followed the EXCAP prescription demonstrated significantly less overall cognitive decline, perceived cognitive impairment, and mental fatigue compared to those receiving usual care alone.

The benefit did not reach statistical significance in patients receiving chemotherapy on three- or four-week cycles. The researchers suggested that the two-week cycle might represent a recovery sweet spot - enough time between treatments for patients to maintain exercise, but not so much time that the exercise effect dissipates.

The walking data underscored the difference. EXCAP participants maintained their daily walking throughout chemotherapy. Those in the control group reduced walking by 53%. Without a structured plan, patients receiving chemotherapy tend to become significantly less active - which may itself contribute to cognitive decline.

What chemo brain costs beyond the clinic

Co-lead author Karen Mustian noted that cancer care providers should consider incorporating structured, home-based exercise prescriptions into routine chemotherapy care. She emphasized that providers should educate patients on the benefits, monitor cognitive and fatigue symptoms throughout treatment, and refer patients to exercise oncology specialists when needed.

Co-lead author Po-Ju Lin added context about why this matters practically: without a structured exercise plan, patients receiving chemotherapy often reduce their daily walking by half and experience notable increases in problems with thinking, memory, and mental fatigue.

Lindsay Peterson, a medical oncologist at Washington University School of Medicine who was not involved in the research, offered an external perspective: for many patients, maintaining the ability to think clearly, remember details, and stay mentally engaged during treatment is essential to preserving independence, continuing to work and care for their families, and sustaining overall quality of life.

Enrollment period and generalizability concerns

The trial enrolled patients between 2009 and 2014, meaning the chemotherapy regimens used may not fully reflect current treatment protocols. Chemotherapy has evolved over the past decade, and newer regimens may produce different cognitive effects or interact differently with exercise.

The patient population was predominantly female with breast cancer. Whether the findings extend to other cancer types, to male patients, or to patients with more advanced disease is unknown. The exclusion of patients with distant metastases limits generalizability to those with earlier-stage cancers.

The exercise intervention was home-based and self-reported. Adherence was tracked through diaries and pedometers, but actual exercise performance was not directly observed. Self-reported data is subject to reporting bias, and the degree to which patients followed the prescription accurately is uncertain.

The cognitive outcomes were patient-reported measures of perceived impairment and fatigue, not objective neuropsychological assessments. While patient-reported outcomes are clinically meaningful, they are subjective and can be influenced by expectations about the benefits of exercise.

And the lack of significant results in three- and four-week cycle patients raises questions. If exercise protects cognition through a biological mechanism, why would the benefit depend on chemotherapy timing? The answer may involve the interaction between exercise frequency and recovery windows, but the current data cannot establish the mechanism.

Low-cost, low-risk, potentially high-value

Despite these limitations, the practical appeal is clear. Walking and resistance bands are safe, inexpensive, and accessible to most patients. Even if the cognitive benefits apply primarily to patients on two-week cycles, that represents a substantial population. And the observation that unstructured patients cut their walking by more than half highlights a secondary problem: chemotherapy-related inactivity that a simple exercise prescription can prevent.

The researchers acknowledged that non-pharmacologic interventions like exercise, cognitive training, and mindfulness are important for managing cognitive impairment during chemotherapy because they are safe, accessible, and can often be delivered at low cost or at home.

For patients dreading chemo brain, the study offers something tangible: evidence that a walking plan and a resistance band might help them keep their minds sharper through treatment.